<DOC>
	<DOCNO>NCT01421043</DOCNO>
	<brief_summary>This study determine whether oral drop formulation triazolam dose 0.25 mg bioequivalent tablet formulation dose 0.25 mg healthy subject .</brief_summary>
	<brief_title>A Study Determine Whether Oral Drops Formulation Triazolam Bioequivalent Tablet Formulation Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Triazolam</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>bioequivalence study</keyword>
	<keyword>triazolam</keyword>
	<keyword>liquid oral drop</keyword>
	<keyword>tablet</keyword>
</DOC>